AstraZeneca PLC (AZN)
NASDAQ: AZN · Real-Time Price · USD
74.22
+0.71 (0.97%)
At close: Feb 21, 2025, 4:00 PM
74.50
+0.28 (0.37%)
After-hours: Feb 21, 2025, 4:41 PM EST
AstraZeneca Revenue
In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth. AstraZeneca had revenue of $14.89B in the quarter ending December 31, 2024, with 23.84% growth.
Revenue (ttm)
$54.07B
Revenue Growth
+18.03%
P/S Ratio
4.24
Revenue / Employee
$582,056
Employees
92,900
Market Cap
229.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
AZN News
- 1 day ago - Final Deadline for the AstraZeneca PLC Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - AZN - PRNewsWire
- 1 day ago - AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline - Investopedia
- 1 day ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit – AZN - GlobeNewsWire
- 1 day ago - Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
- 1 day ago - FibroGen sells China unit to AstraZeneca in deal worth $160 million - Reuters
- 2 days ago - AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold - Seeking Alpha
- 2 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - GlobeNewsWire
- 5 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca - Accesswire